In support of this, complete inhibition of GSK3β with MeBIO caused a significant increase in GLI1 expression, whereas the introduction of constitutively active GSK3β by the transfection of breast cancer cells enhanced drug retention ability that is abrogated by OPN treatment. The gene discussed is GLI1; the disease is breast cancer.